JP2018511581A - 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤 - Google Patents

線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤 Download PDF

Info

Publication number
JP2018511581A
JP2018511581A JP2017546676A JP2017546676A JP2018511581A JP 2018511581 A JP2018511581 A JP 2018511581A JP 2017546676 A JP2017546676 A JP 2017546676A JP 2017546676 A JP2017546676 A JP 2017546676A JP 2018511581 A JP2018511581 A JP 2018511581A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
substituted
ch2x
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017546676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511581A5 (cg-RX-API-DMAC7.html
Inventor
マーコウィッツ,サンフォード
ジェルソン,スタントン
デサイ,アマル
ジン ホー,ウォン
ジン ホー,ウォン
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ, ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2018511581A publication Critical patent/JP2018511581A/ja
Publication of JP2018511581A5 publication Critical patent/JP2018511581A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017546676A 2015-03-08 2016-03-08 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤 Pending JP2018511581A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129885P 2015-03-08 2015-03-08
US62/129,885 2015-03-08
PCT/US2016/021374 WO2016144958A1 (en) 2015-03-08 2016-03-08 Inhibitors of short-chain dehydrogenase activity for treating fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020192961A Division JP7282067B2 (ja) 2015-03-08 2020-11-20 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤

Publications (2)

Publication Number Publication Date
JP2018511581A true JP2018511581A (ja) 2018-04-26
JP2018511581A5 JP2018511581A5 (cg-RX-API-DMAC7.html) 2019-05-09

Family

ID=56879350

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017546676A Pending JP2018511581A (ja) 2015-03-08 2016-03-08 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2020192961A Active JP7282067B2 (ja) 2015-03-08 2020-11-20 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2023080881A Pending JP2023103379A (ja) 2015-03-08 2023-05-16 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020192961A Active JP7282067B2 (ja) 2015-03-08 2020-11-20 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2023080881A Pending JP2023103379A (ja) 2015-03-08 2023-05-16 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤

Country Status (8)

Country Link
US (3) US10945998B2 (cg-RX-API-DMAC7.html)
EP (1) EP3267995B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018511581A (cg-RX-API-DMAC7.html)
CN (2) CN107921025A (cg-RX-API-DMAC7.html)
AU (3) AU2016229918B2 (cg-RX-API-DMAC7.html)
CA (1) CA2979203A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250636A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016144958A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
US10869871B2 (en) 2013-10-15 2020-12-22 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2021038247A (ja) * 2015-03-08 2021-03-11 ケース ウエスタン リザーブ ユニバーシティ 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2023515081A (ja) * 2020-02-21 2023-04-12 ケース ウエスタン リザーブ ユニバーシティ 腎損傷を治療するための組成物および方法
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
JP7178360B2 (ja) 2017-04-07 2022-11-25 ケース ウエスタン リザーブ ユニバーシティ 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
EP3630773A1 (en) * 2017-05-26 2020-04-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 15-pgdh阻害薬
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
JP7677983B2 (ja) 2020-01-23 2025-05-15 マイオフォルテ セラピューティクス,インク. Pgdh阻害剤、およびその作製と使用の方法
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
WO2021252936A1 (en) * 2020-06-11 2021-12-16 The Board Of Trustees Of The Leland Stanford Junior University Rejuvenation of aged tissues and organs by inhibition of the pge2 degrading enzyme, 15-pgdh
EP4228650A4 (en) * 2020-10-15 2024-12-18 Myoforte Therapeutics Inc. INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
WO2023076986A1 (en) * 2021-10-27 2023-05-04 The Board Of Trustees Of The Leland Stanford Junior University Regeneration or rejuvenation of tissues and organs
CN114875003B (zh) * 2022-04-06 2024-05-24 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
TW202434597A (zh) * 2022-11-14 2024-09-01 大陸商武漢人福創新藥物研發中心有限公司 抑制15-pgdh的化合物及其用途
CN118515655A (zh) * 2023-02-17 2024-08-20 武汉人福创新药物研发中心有限公司 亚砜类化合物及其用途
CN121772923A (zh) * 2023-06-28 2026-03-31 埃皮里姆生物股份有限公司 用于治疗与升高的15-pgdh相关的病况的间歇给药方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158649A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
WO2013180336A1 (ko) * 2012-05-30 2013-12-05 조선대학교 산학협력단 15-히드록시프로타글란딘 디히드로게나제 및 pge2 활성을 조절하는 황칠나무 추출물의 용도
JP6517197B2 (ja) * 2013-10-15 2019-05-22 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US5445164A (en) 1993-05-11 1995-08-29 Gynetech, Inc. Cervical tissue sampling device
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
US6214533B1 (en) 1998-04-10 2001-04-10 Konica Corporation Thermally developable photosensitive material
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
EP1080728A1 (en) * 1999-03-16 2001-03-07 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US7004913B1 (en) 2001-05-04 2006-02-28 Cdx Laboratories, Inc. Retractable brush for use with endoscope for brush biopsy
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EP1594438B1 (fr) 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
JP2005325099A (ja) 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
EP1781289A1 (en) * 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
US20070071699A1 (en) 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
US20070078175A1 (en) 2005-10-05 2007-04-05 L'oreal Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof
DE602006016643D1 (de) 2005-12-20 2010-10-14 Richter Gedeon Nyrt THIENOÄ2,3-bÜPYRIDIN DERIVATE
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
JP2011512346A (ja) * 2008-02-15 2011-04-21 ノボビオン オイ クルクミンの可溶性錯体
US7629112B1 (en) * 2008-05-30 2009-12-08 Eastman Kodak Company Color photographic materials with yellow minimum density colorants
US20100093764A1 (en) 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2383263B1 (en) 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
EP2308883A1 (en) 2009-10-05 2011-04-13 Centre National De La Recherche Scientifique New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
EP2806876A4 (en) * 2012-01-25 2016-03-02 Proteostasis Therapeutics Inc Proteasome activity enhancing compounds
WO2016144958A1 (en) 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2014160947A1 (en) 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
EP3525308A1 (en) 2013-07-10 2019-08-14 Revive Electronics LLC Apparatuses and methods for controlling power to electronic devices
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3283074A4 (en) 2015-04-14 2018-12-05 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3031091A1 (en) 2016-07-18 2018-01-25 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7178360B2 (ja) 2017-04-07 2022-11-25 ケース ウエスタン リザーブ ユニバーシティ 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
JP2021134242A (ja) 2020-02-25 2021-09-13 株式会社アイティー技研 鉱物油精製方法及び装置
JP7574640B2 (ja) 2020-12-23 2024-10-29 株式会社リコー 画像処理装置、画像処理システム、方法およびプログラム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158649A1 (en) * 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
WO2013180336A1 (ko) * 2012-05-30 2013-12-05 조선대학교 산학협력단 15-히드록시프로타글란딘 디히드로게나제 및 pge2 활성을 조절하는 황칠나무 추출물의 용도
JP6517197B2 (ja) * 2013-10-15 2019-05-22 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR LIBRARIES, PATHWAYS TO DISCOVERY, 2011, RETRIEVED FROM THE INTERNET: HTTPS://WWW.NCBI.NLM., JPN6019050612, ISSN: 0004182170 *
PPAR RESEARCH, 2007, ARTICLE ID 71323,P.1-10, JPN6019050610, ISSN: 0004182169 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869871B2 (en) 2013-10-15 2020-12-22 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP2021038247A (ja) * 2015-03-08 2021-03-11 ケース ウエスタン リザーブ ユニバーシティ 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
US10945998B2 (en) 2015-03-08 2021-03-16 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
JP7282067B2 (ja) 2015-03-08 2023-05-26 ケース ウエスタン リザーブ ユニバーシティ 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
US12616681B2 (en) 2019-04-04 2026-05-05 Case Western Reserve University Compositions and methods for treating renal injury
JP2023515081A (ja) * 2020-02-21 2023-04-12 ケース ウエスタン リザーブ ユニバーシティ 腎損傷を治療するための組成物および方法

Also Published As

Publication number Publication date
AU2016229918B2 (en) 2020-10-29
US10945998B2 (en) 2021-03-16
JP7282067B2 (ja) 2023-05-26
EP3267995A4 (en) 2019-02-27
EP3267995B1 (en) 2025-10-08
JP2023103379A (ja) 2023-07-26
WO2016144958A1 (en) 2016-09-15
US20210283113A1 (en) 2021-09-16
AU2016229918A1 (en) 2017-09-28
JP2021038247A (ja) 2021-03-11
EP3267995A1 (en) 2018-01-17
AU2021200610B2 (en) 2022-09-15
HK1250636A1 (zh) 2019-01-11
CN107921025A (zh) 2018-04-17
CN118059093A (zh) 2024-05-24
US20250295640A1 (en) 2025-09-25
AU2022287625A1 (en) 2023-02-02
AU2021200610A1 (en) 2021-03-04
CA2979203A1 (en) 2016-09-15
US20180064694A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
JP7282067B2 (ja) 線維症を処置するための短鎖デヒドロゲナーゼ活性阻害剤
JP2018511581A5 (cg-RX-API-DMAC7.html)
JP7139308B2 (ja) 神経新生の促進及びニュ-ロン細胞死の阻害のための短鎖脱水素酵素活性の阻害剤
JP6789542B2 (ja) 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
US20250243217A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
CN111132982A (zh) 调节短链脱氢酶活性的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200721